Development of a sexual function questionnaire for clinical trials of female sexual dysfunction

被引:150
作者
Quirk, FH
Heiman, JR
Rosen, RC
Laan, E
Smith, MD
Boolell, M
机构
[1] Pfizer Ltd, Cent Res, Pfizer Global Res & Dev, Sandwich CT13 9NJ, Kent, England
[2] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA
[3] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, Piscataway, NJ 08854 USA
[4] Univ Amsterdam, Dept Clin Psychol, NL-1018 WB Amsterdam, Netherlands
来源
JOURNAL OF WOMENS HEALTH & GENDER-BASED MEDICINE | 2002年 / 11卷 / 03期
关键词
D O I
10.1089/152460902753668475
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: To better evaluate efficacy in clinical trials of drugs as potential treatments for female sexual dysfunctions (FSD), a brief, multidimensional measure of female sexual function was developed. Methods: Data from semistructured interviews with 82 women with or without FSD, aged 19-65 years, generated a pool of 61 items that addressed aspects of female sexual function. On review by a panel, individual items were selected for face validity and clinical relevance. Thirty-one items were used as a sexual function questionnaire (SFQ-V1) in two multicenter, phase II clinical trials totaling 781 women with FSD. Normative data were generated from a sample of 201 women without FSD. Results: Factor analysis produced seven domains of female sexual function: desire, physical arousal-sensation, physical arousal-lubrication, enjoyment, orgasm, pain, and partner relationship. The internal consistency of the domains ranged from 0.65 to 0.91, and test-retest reliability ranged from 0.21 to 0.71 for Cohen's weighted kappa and 0.42 to 0.78 for Pearson's correlation coefficient. There was a significant difference between the baseline mean SFQ domain scores of patients with FSD compared with those of women without FSD (p < 0.0001). End-of-study SFQ scores were significantly different for women who reported improvement vs. women who reported no improvement (p < 0.001). Conclusions: The SFQ produced seven domains of female sexual function with excellent internal consistency, moderate to good reliability, excellent discriminant validity, and sensitivity. The results suggest that the SFQ may be a valuable new tool for evaluating and diagnosing subsets of FSD and, ultimately, for evaluating treatments of these disorders.
引用
收藏
页码:277 / 289
页数:13
相关论文
共 27 条
  • [1] Report of the international consensus development conference on female sexual dysfunction: Definitions and classifications
    Basson, R
    Berman, J
    Burnett, A
    Derogatis, L
    Ferguson, D
    Fourcroy, J
    Goldstein, I
    Graziottin, A
    Heiman, J
    Laan, E
    Leiblum, S
    Padma-Nathan, H
    Rosen, R
    Segraves, K
    Segraves, RT
    Shabsigh, R
    Sipski, M
    Wagner, G
    Whipple, B
    [J]. JOURNAL OF UROLOGY, 2000, 163 (03) : 888 - 893
  • [2] The female sexual response: A different model
    Basson, R
    [J]. JOURNAL OF SEX & MARITAL THERAPY, 2000, 26 (01) : 51 - 65
  • [3] BASSON R, 2000, OBSTET GYNECOL S1, V95, pS54
  • [4] STATISTICAL-METHODS FOR ASSESSING OBSERVER VARIABILITY IN CLINICAL MEASURES
    BRENNAN, P
    SILMAN, A
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1992, 304 (6840): : 1491 - 1494
  • [5] DSFI - MULTIDIMENSIONAL MEASURE OF SEXUAL FUNCTIONING
    DEROGATIS, LR
    MELISARATOS, N
    [J]. JOURNAL OF SEX & MARITAL THERAPY, 1979, 5 (03) : 244 - 281
  • [6] Derogatis LR, 1997, J SEX MARITAL THER, V23, P291
  • [7] Fourcroy JL, 1998, INT J IMPOT RES, V10, pS121
  • [8] On life satisfaction in male erectile dysfunction
    FuglMeyer, AR
    Lodnert, G
    Branholm, IB
    FuglMeyer, KS
    [J]. INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 1997, 9 (03) : 141 - 148
  • [9] HEIMAN J, 2000, INT J FERTIL WOMEN M, V45, P200
  • [10] Heiman JR, 1998, INT J IMPOT RES, V10, pS94